Payment overview · 2025
General Payments
$258.55
14 reported records · 10 companies
Healthcare provider profile · identity verified
Misty Dawn Cain, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FARMINGTON, MO · NPI 1013548403
Verified facts
What the public records show
CMS Open Payments records show Misty Dawn Cain, FNP received $258.55 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMTUZA as an associated drug or biological on 44 records involving 34 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symtuza by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.88 | 20.8% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $37.20 | 14.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.54 | 12.2% | 2 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $28.82 | 11.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.53 | 9.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.17 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.51 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.32 | 6.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.80 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.78 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.55 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.88 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SYMTUZA open payments reported associated product |
CMS Open Payments — General Payments 44 supporting records · 34 recipient NPIs · example record 1174329506 |
Symtuza · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 1349 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1130 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 958 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 932 | 42 |
| Omeprazole | Omeprazole | 846 | 50 |
| Gabapentin | Gabapentin | 718 | 53 |
| Lisinopril | Lisinopril | 713 | 47 |
| Potassium Chloride | Potassium Chloride | 469 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 32 |
| Montelukast Sodium | Montelukast Sodium | 421 | 16 |
| Trazodone Hcl | Trazodone Hcl | 408 | 25 |
| Furosemide | Furosemide | 406 | 47 |
| Famotidine | Famotidine | 378 | 26 |
| Metformin Hcl | Metformin Hcl | 371 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 273 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 15 |
| Buspirone Hcl | Buspirone Hcl | 240 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 17 |
| Ibuprofen | Ibuprofen | 228 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 224 | 14 |
| Divalproex Sodium | Divalproex Sodium | 220 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 218 | suppressed |
| Simvastatin | Simvastatin | 207 | suppressed |
| Meloxicam | Meloxicam | 199 | 14 |
| Mirtazapine | Mirtazapine | 195 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 19 |
| Finasteride | Finasteride | 167 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 166 | 33 |
| Sertraline Hcl | Sertraline Hcl | 166 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 145 | 41 |
| Propranolol Hcl | Propranolol Hcl | 142 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 139 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 138 | suppressed |
| Prednisone | Prednisone | 132 | 65 |
| Topiramate | Topiramate | 131 | suppressed |
| Celecoxib | Celecoxib | 130 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 125 | suppressed |
| Spironolactone | Spironolactone | 124 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 24 |
| Sucralfate | Sucralfate | 121 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 35 |
| Prazosin Hcl | Prazosin Hcl | 115 | suppressed |
| Ketoconazole | Ketoconazole | 114 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | suppressed |
| Januvia | Sitagliptin Phosphate | 112 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 109 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 108 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 15 |
| Carvedilol | Carvedilol | 103 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 13 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 99 | suppressed |
| Levetiracetam | Levetiracetam | 97 | suppressed |
| Mupirocin | Mupirocin | 96 | 52 |
| Eliquis | Apixaban | 92 | suppressed |
| Jardiance | Empagliflozin | 92 | suppressed |
| Loperamide | Loperamide Hcl | 92 | 33 |
| Atenolol | Atenolol | 89 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 88 | suppressed |
| Losartan Potassium | Losartan Potassium | 86 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 84 | suppressed |
| Myrbetriq | Mirabegron | 82 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 78 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 62 |
| Clonidine Hcl | Clonidine Hcl | 77 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 53 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 74 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 38 |
| Desmopressin Acetate | Desmopressin Acetate | 73 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 72 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 68 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | suppressed |
| Primidone | Primidone | 66 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 64 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | suppressed |
| Chlorthalidone | Chlorthalidone | 60 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 60 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 59 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 14 |
| Ranolazine Er | Ranolazine | 55 | suppressed |
| Azithromycin | Azithromycin | 54 | 47 |
| Allopurinol | Allopurinol | 53 | suppressed |
| Acyclovir | Acyclovir | 52 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 52 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 11 |
| Fluconazole | Fluconazole | 49 | 26 |
| Baclofen | Baclofen | 43 | suppressed |
| Paliperidone Er | Paliperidone | 43 | suppressed |
| Olanzapine | Olanzapine | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 19 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 27 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Phenytoin | Phenytoin | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 21 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Acarbose | Acarbose | 24 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 12 |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 18 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 12 |
| Constulose | Lactulose | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Permethrin | Permethrin | 17 | 11 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Pindolol | Pindolol | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Desloratadine | Desloratadine | 14 | suppressed |
| Ivermectin | Ivermectin | 14 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Triamterene | Triamterene | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.55 · 14 records | ABBVIE INC. | AIRSUPRA, BREZTRI, Bimzelx, HYRIMOZ, KISUNLA, REXULTI, SPRAVATO, Senza, VRAYLAR, Wegovy, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error